A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)

INTRODUCTION: Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study objectives were to determine the recommended phase 2 dose (RPTD) of veliparib plus carboplatin and paclitaxel, and assess pharmacokinetics (PK), tolerabil...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizugaki, Hidenori, Yamamoto, Noboru, Nokihara, Hiroshi, Fujiwara, Yutaka, Horinouchi, Hidehito, Kanda, Shintaro, Kitazono, Satoru, Yagishita, Shigehiro, Xiong, Hao, Qian, Jane, Hashiba, Hideyuki, Shepherd, Stacie P., Giranda, Vincent, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612330/
https://www.ncbi.nlm.nih.gov/pubmed/26433581
http://dx.doi.org/10.1007/s00280-015-2876-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612330/
https://www.ncbi.nlm.nih.gov/pubmed/26433581
http://dx.doi.org/10.1007/s00280-015-2876-7

Ejemplares similares